ATE253593T1 - Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit - Google Patents

Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit

Info

Publication number
ATE253593T1
ATE253593T1 AT97934467T AT97934467T ATE253593T1 AT E253593 T1 ATE253593 T1 AT E253593T1 AT 97934467 T AT97934467 T AT 97934467T AT 97934467 T AT97934467 T AT 97934467T AT E253593 T1 ATE253593 T1 AT E253593T1
Authority
AT
Austria
Prior art keywords
igsf
domains
fragments
modification
fusion proteins
Prior art date
Application number
AT97934467T
Other languages
English (en)
Inventor
Andreas Plueckthun
Lars Nieba
Annemarie Honegger
Original Assignee
Plueckthun Andreas Prof Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plueckthun Andreas Prof Dr filed Critical Plueckthun Andreas Prof Dr
Application granted granted Critical
Publication of ATE253593T1 publication Critical patent/ATE253593T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97934467T 1996-07-16 1997-07-16 Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit ATE253593T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96111441 1996-07-16
PCT/EP1997/003792 WO1998002462A1 (en) 1996-07-16 1997-07-16 Immunoglobulin superfamily domains and fragments with increased solubility

Publications (1)

Publication Number Publication Date
ATE253593T1 true ATE253593T1 (de) 2003-11-15

Family

ID=8222993

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934467T ATE253593T1 (de) 1996-07-16 1997-07-16 Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit

Country Status (7)

Country Link
US (1) US6815540B1 (de)
EP (1) EP0938506B1 (de)
JP (1) JP2000516452A (de)
AT (1) ATE253593T1 (de)
CA (1) CA2267620A1 (de)
DE (1) DE69726003T2 (de)
WO (1) WO1998002462A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
AU1631000A (en) * 1998-11-19 2000-06-05 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
EP1737890A2 (de) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulinvarianten ausserhalb der fc-region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
JP5080269B2 (ja) 2004-12-07 2012-11-21 ロンザ アーゲー メリビオースオペロン発現系
CA2589937C (en) 2004-12-07 2014-04-22 Lonza Ag Rhamnose promoter expression system
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
JP5142707B2 (ja) * 2005-02-08 2013-02-13 一般財団法人化学及血清療法研究所 抗体の改良方法
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
BRPI0710971A2 (pt) 2006-04-28 2011-05-31 Esbatech Ag anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk
CA2653661A1 (en) * 2006-05-31 2007-12-06 Astellas Pharma Inc. Humanized anti-human osteopontin antibody
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
WO2008036688A2 (en) 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0819598A2 (pt) 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
HRP20150279T1 (hr) 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
PL2307458T3 (pl) * 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
KR20210097819A (ko) * 2008-06-25 2021-08-09 노바르티스 아게 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
BRPI0914251B1 (pt) 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
AU2013203477B2 (en) * 2008-06-25 2015-02-12 Novartis Ag Solubility optimization of immunobinders
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX352922B (es) * 2009-02-24 2017-12-14 Esbatech Alcon Biomed Res Unit Métodos para identificar inmunoligadores de los antígenos de la superficie celular.
AU2010217120B2 (en) * 2009-02-24 2014-11-20 Novartis Ag Methods for identifying immunobinders of cell-surface antigens
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DE102009047243A1 (de) * 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
KR101721187B1 (ko) 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP3604339B1 (de) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutische antikörper gegen das ror-1-protein und verfahren zur verwendung davon
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2016001810A1 (en) 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
KR102295681B1 (ko) * 2016-05-19 2021-08-27 위스콘신 얼럼나이 리서어치 화운데이션 생물학적 분자의 용매 접근성 및 3차원 구조를 연구하기 위한 방법, 시스템, 및 조성물
CN113272322A (zh) * 2018-10-08 2021-08-17 Uab 研究基金会 神经内分泌癌靶向治疗
MY195550A (en) 2018-10-29 2023-01-31 Hoffmann La Roche Antibody Formulation
US20230054648A1 (en) * 2021-05-03 2023-02-23 Agilent Technologies, Inc. Chimeric immunogens and methods for making polyclonal antibodies against specific epitopes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB9016299D0 (en) * 1990-07-25 1990-09-12 Brien Caroline J O Binding substances
US6485943B2 (en) * 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions

Also Published As

Publication number Publication date
EP0938506B1 (de) 2003-11-05
WO1998002462A1 (en) 1998-01-22
EP0938506A1 (de) 1999-09-01
DE69726003D1 (de) 2003-12-11
JP2000516452A (ja) 2000-12-12
CA2267620A1 (en) 1998-01-22
DE69726003T2 (de) 2004-08-26
US6815540B1 (en) 2004-11-09

Similar Documents

Publication Publication Date Title
ATE253593T1 (de) Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
WO1999055868A3 (en) Fizz proteins
Bhakdi et al. Isolation of the terminal complement complex from target sheep erythrocyte membranes
CY1111097T1 (el) Πρωτεϊνη δεσμευσης του υποδοχεα nogo
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
CA2068222A1 (en) Monoclonal antibodies
Journet et al. Requirement for Both D Domains of the Propolypeptide in von Willebrand Factor Muitimerization and Storage
AU2002363465A1 (en) Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
DE69611896D1 (de) Fusions-DNS-Sequenz, dadurch exprimiertes Fusionsprotein und Verfahren zur Expression dieses Fusionsproteins
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
IL139272A0 (en) New peptide fragments for protein purification
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz
Kumazaki et al. Comparative study on fibers isolated from four R-type pyocins, phage-tail-like bacteriocins of Pseudomonas aeruginosa
WO2001014536A3 (de) Nukleinsäuremolekül, umfassend eine für ein hämocyanin kodierende nukleinsäuresequenz und mindestens eine intronsequenz
WO1999042586A3 (en) Exo1 and exo2, exocytotic proteins
EP1241179A3 (de) Menschliches Cornichon-ähliches Protein und dafür kodierende Nukleinsäure
DK1270590T3 (da) Protein, som fremmer overlevelse af stavformede fotoreceptorceller og nucleinsyre kodende herfor
EP1251139A3 (de) Menschliches mindin-ähliches Protein und dafür kodierende Nukleinsäure
EP2050762A3 (de) Neue Polypeptide und für diese kodierende Nukleinsäuren
Matsugu et al. Improved antigen detection on western blots
DK1241251T3 (da) Humant prostasin-lignende protein og nukleinsyrer kodende for samme
EP1247817A3 (de) Menschliches CD-23-ähliches Protein und dafür kodierende Nukleinsäure
EP1241252A3 (de) Menschliches Enteropeptidase-ähnliches Protein und dafür kodierende Nukleinsäure
EP1241184A3 (de) Menschliches Synaptogyrin-ähnliches Protein und dafür kodierende Nukleinsäure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0938506

Country of ref document: EP

REN Ceased due to non-payment of the annual fee